MARKET

AEMD

AEMD

Aethlon Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.028
+0.038
+3.87%
Opening 13:11 07/07 EDT
OPEN
1.010
PREV CLOSE
0.9900
HIGH
1.030
LOW
0.9903
VOLUME
103.00K
TURNOVER
81.40K
52 WEEK HIGH
6.22
52 WEEK LOW
0.8800
MARKET CAP
16.28M
P/E (TTM)
-1.4609
1D
5D
1M
3M
1Y
5Y
At Least Three Probable Cases of Monkeypox Have Been Identified in San Francisco
-KPIX 5 https://www.cbsnews.com/sanfrancisco/news/monkeypox-sfdph-officials-identify-3-additional-cases/
Benzinga · 7h ago
'The Community already exceeds 1,000 cases of monkeypox after adding another 90 positives in the last hours' - europress.es
https://www.europapress.es/madrid/noticia-comunidad-supera-ya-1000-casos-viruela-mono-sumar-otros-90-positivos-ultimas-horas-20220705150221.html
Benzinga · 2d ago
AEMD: Positive Results in a Range of Conditions, Including COVID-19 & Monkeypox
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT
Benzinga · 3d ago
ArcelorMittal, Universal Health Services, RH among premarket losers' pack
Renalytix (RNLX) -28% on <a href="https://seekingalpha.com/news/3853151-renalytix-ai...
Seekingalpha · 06/30 12:55
First Probable Case of Monkeypox in Michigan Identified in Oakland County
https://www.9and10news.com/2022/06/29/first-probable-case-of-monkeypox-identified-in-oakland-county/
Benzinga · 06/29 23:40
'First probable case of Monkeypox identified in New Hampshire' -Local NBC Outlet
https://www.mynbc5.com/article/first-case-monkeypox-in-new-hampshire/40462421?utm_campaign=snd-autopilot
Benzinga · 06/29 20:24
Aethlon Medical Earnings Perspective: Return On Capital Employed
Aethlon Medical (NASDAQ:AEMD) brought in sales totaling $13.12 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 49.75%, resulting in a loss of $3.79 million.
Benzinga · 06/29 13:50
BRIEF-Aethlon Medical Announces Fiscal Year End Financial Results
BRIEF-Aethlon Medical Announces Fiscal Year End Financial Results
Reuters · 06/28 20:41
More
No Data
Learn about the latest financial forecast of AEMD. Analyze the recent business situations of Aethlon Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AEMD stock price target is 7.00 with a high estimate of 9.00 and a low estimate of 4.000.
High9.00
Average7.00
Low4.000
Current 1.028
EPS
Actual
Estimate
-0.21-0.16-0.10-0.05
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Institutional Holdings
Institutions: 37
Institutional Holdings: 1.40M
% Owned: 8.87%
Shares Outstanding: 15.83M
TypeInstitutionsShares
Increased
5
35.38K
New
4
20.18K
Decreased
8
232.06K
Sold Out
4
80.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.29%
Healthcare Equipment & Supplies
+0.31%
Key Executives
Non-Executive Chairman/Independent Director
Edward Broenniman
Chief Executive Officer/Director
Charles Fisher
Chief Financial Officer/Senior Vice President - Finance/Secretary
James Frakes
Senior Vice President/Director
Guy Cipriani
Other
Steven Larosa
Director
Angela Rossetti
Independent Director
Chetan Shah
No Data
No Data
About AEMD
Aethlon Medical, Inc. (Aethlon) is a biotechnology company. The Company is focused on developing products to diagnose and treat life and organ-threatening diseases. It is involved in developing the Hemopurifier, a therapeutic blood filtration system indicated for infectious diseases and cancer. The Company operates through two segments: Aethlon and ESI. The Aethlon segment represents its therapeutic business activities. The ESI segment represents its diagnostic business. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seeding the spread of metastasis. The Company is conducting clinical trials in patients with advanced and metastatic head and neck cancer. It is focused on the treatment of solid tumors that are being treated with checkpoint inhibitors. Hemopurifier have been used to treat individuals infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and Ebola.

Webull offers kinds of Aethlon Medical, Inc. stock information, including NASDAQ:AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.